Precision Medicine Approaches to Renal Osteodystrophy
Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is not practical in the clinic for the vast majority of kidney disease patients and parathyroid hormone and bone alkaline phosphatase have insufficient accuracy for turnover type to safely and confidently guide treatment of renal osteodystrophy. In the present investigation, the investigators will study a microRNA approach as a novel non-invasive biomarker of turnover for renal osteodystrophy.
• Study participant has provided informed consent
• Age ≥ 18 years
• CKD Stages 3-5D regardless of kidney transplantation status
• CKD5D patients receiving maintenance hemodialysis for at least 3 months
• Clinically indicated treatment for renal hyperparathyroidism, renal osteodystrophy and/or Osteoporosis
• PTH, BSAP and CTX meets defined thresholds for low or high turnover ROD type or a Bone biopsy evidence of low or high turnover based